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The microbial risk to patients from aseptically manufactured pharmaceuticals is dependent on the
chance that a product contains sufficient microbes to initiate an infection. This possibility is
dependent on risk factors associated with the method of production and product formulation, and
can be calculated. An analysis of these risk factors can be used to minimise patient risk and assist in
determining the appropriate level of contamination control required for manufacturing.
Introduction
To determine the cleanliness standards required during
pharmaceutical production, and the effort required to control
and monitor the associated hazards, the degree of microbial
risk to the patient should be considered. Products with a
greater microbial risk require a cleaner environment, more
effective controls, and more critical monitoring methods.
Regulatory authorities accept that pharmaceutical products
with a low microbial risk to patients can be produced in an
environment with lower cleanliness standards than products
with a higher risk. For example, aseptically produced
pharmaceutical products applied topically or administered via
body orifices need not be sterile and can be manufactured in
cleanrooms with lower environmental standards than those
required for sterile products. It is also accepted that terminally
sterilised products do not require as high cleanliness
standards as those produced aseptically1.
For aseptically produced parenterals, it is tacitly accepted
that different pharmaceutical products have different risks of
infecting a patient, and therefore require different cleanliness
standards. Little or no advice is available on this topic, from
regulatory or other sources.
Patients can be infected with microorganisms during the
administration and use of pharmaceutical products. There is
also a probability of a risk from the use of multidose
containers. This paper does not consider these risks but only
the risk from microbes in a product before administration to
the patient.
Several factors influence the likelihood that a
pharmaceutical product can infect a patient. These are:
1. The probability that a pharmaceutical product contains
microorganisms immediately after manufacture. This
depends on:
• the likelihood of the product being contaminated
during production, and, 
• the treatments given to the product during, or at the end
of production, that will kill or eliminate micro-
organisms.
2. The ability of the product formulation to support the
growth or survival of microorganisms, from the
completion of manufacture until administered to the
patient, i.e. during its shelf life;
These risks are best assessed for a specific manufacturing
area, process, product type and formulation.
Probability that a pharmaceutical product
contains microorganisms immediately
after manufacture
The probability that a product contains microorganisms
immediately after manufacture is dependent on a
microorganism being deposited onto it during manufacture,
and whether any such microorganism is killed or eliminated
during the process.
Microbial contamination during manufacture
An estimate of microbial contamination during manufacture
can be obtained by the following methods.
Estimate from product simulation tests
The amount of microbial contamination during production is
best estimated by process simulation tests (PSTs), such as
carried out by filling containers with bacteriological growth
promoting broth. PSTs do not simulate exactly the microbial
contamination expected during routine production, as they are
often devised to have a greater microbial challenge than
normal e.g. there can be more process interventions.
However, it is reasonable to consider that they usually
estimate microbial contamination rates close to the ‘worst
case scenario’.
If sufficient product simulation tests have been completed
this provides an estimate of the proportion of products
contaminated at the end of production. However, during
initial development of the manufacturing process, or if
manufacturing has been established for a short time only,
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airborne deposition for 1 minute; this is the time, after
sterilisation, when the product is open to airborne
contamination until closed.
The average number of airborne microbe carrying
particles found to deposit onto settle plates of 14cm
diameter (154cm2), exposed during filling in the filling
area for over 100 exposures of 4 hours, was 0.1 per plate
The deposition rate i.e. the number of microbe carrying
particles that will deposit onto a given area of surface in a
given time (no.cm-2.h-1) of the microorganisms in the
filling area can be calculated from this settle plate data as
follows.
Deposition rate (no.cm-2.h-1) = average count on settle
plate ÷[area of plate (cm2) × time plate exposed (h)]
= 0.1 ÷[154 × 4] = 1.6 × 10-4
The number of microbe carrying particles that will
deposited from air onto, or into, a known area of the
product (1cm2) open to contamination for a known time
(1/60th hr) can now be calculated i.e.
Number of microbe carrying particles deposited from air
onto the product = deposition rate (no.cm-2.h-1) × surface
area exposed (cm2) × time product exposed (h)
= 1.6 × 10-4 × 1 × [1 ÷ 60] = 2.7 × 10-6
Because the activity of personnel is distributed through
the process, airborne microbial deposition into the
product will occur throughout manufacture and will be
distributed randomly5. The number of microbe carrying
particles deposited from the air i.e. 2.7 × 10-6 therefore
relates to a contamination rate of 3 contaminated
containers in 1,000,000 containers.
Filling was known to utilise a reliable automatic
machine, which required very little attention or
intervention, and a risk assessment concluded that the
possibility of contamination from surface contact or other
sources contributed very little additional contamination.
It was therefore considered that the proportion of
there are unlikely to be sufficient results to
provide a good estimate. In these cases it is best
to enhance these results by further information
obtained by risk assessment and calculation.
Estimate by risk assessment and calculation
The risk of microbial contamination during
aseptic manufacture will vary according to the
type of manufacturing process. Shown in Table
1 is an indication of likely microbial
contamination rates to be found during
different types of aseptic manufacture. This
table is based on known theoretical
calculations, research and practical results. 
It is known that that amount of airborne
microbial contamination can be calculated from
a fundamental equation that relates airborne
contamination to:
(a) the surface area of the product exposed to
the deposition of microorganisms from the air, 
(b) the time the product is exposed and, 
(c) the deposition rate of airborne microorganisms
present in the critical area2,3. It has also been
established that the more frequently products are
contacted by contaminated surfaces, such as gloves,
the more likely they will be contaminated4. Thus,
microbial contamination of the product has been
shown to decrease as both the airborne and surface
contact factors decrease, from about 1 in 103 to less
than 1 in 106 products3, 5. It should be noted that the
first row of Table 1 suggests that for the associated
type of manufacturing process there would be an
unacceptable contamination rate of 1 in 103. It would
be abnormal with current manufacturing conditions to
have such types of processes but, if they did exist, it is
the likely contamination rate.
Table 1 only provides an approximation of the likely
contamination rate. A more accurate alternative is to
calculate the likely airborne contamination rate and then
modify it by using an estimate of the risk of contamination
caused by surface contact.  
Most microbes exist in the cleanroom air rafted on
particles of skin, their average size being between about
8µm and 20µm2, 6, and these microbe-carrying particles
can deposit into, or onto, the product. The amount of
deposition, and hence the airborne contamination of the
product, can be calculated using the method described by
Whyte and Eaton7, 8. In addition to this it is necessary to
estimate the contamination from other sources such as
surface contact. This is more difficult and is best done by
using a risk assessment technique to compare the amount
of contamination from non-airborne sources with the
calculated amount of airborne contamination. Two such
examples are given below, and based on the risk
assessment method more fully explained in the paper of
Whyte and Eaton8.
Example 1:
Containers with an internal neck area of 1cm2 are open to
Table 1. Likely product contamination rates by microorganisms for various types
of aseptic manufacturing
Type of process Likely 
contamination 
rate 
Product that has: 
(a) large area for deposition, 
(b) long exposure time, and 
(c) manual interventions 
occur often during production 1 in 103
Product has two of the factors (a), (b) or (c) given above 1 in 104
Product has one of the factors (a), (b) or (c) given above 1 in 105
Product has small deposition area, a short exposure time, 
and there is little or no intervention during production 1 in 106
Manufactured within a barrier system* less than 1 in 106
* isolator, or a unidirectional workstation with a physical barrier through which
manipulations are carried out with gauntlets or half-suits.
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containers contaminated during production was the same
as that calculated for airborne contamination i.e. 3
containers in 1,000,000.
Example 2:
A solid product with a surface area of 2cm2 was
aseptically produced by a process that left the product
exposed for 10 min. The average settle plate count was the
same as for the previous example 1, and hence the
deposition rate was 1.6 x 10-4 .cm-2.h-1. The number of
microbe carrying particles that will deposit from air onto
the product can be calculated as:
Number of microbe carrying particles deposited from air
onto the product = deposition rate (no.cm-2.h-1) × surface
area (cm2) × time product exposed (h)
= 1.6 × 10-4 × 2 × [10 ÷ 60] = 5.3 × 10-5 i.e. 5
contaminated containers in 100,000 containers.
The process machinery was complicated to set up and
needed attention during normal production, and there
were many unplanned interventions. A risk assessment
concluded that the contribution of microbial
contamination from surface contact and other sources
was likely to be 10 times more than from the air and this
factor was applied to give a contamination rate during
production of 5.3 × 10-4 i.e. 5 contaminated containers in
10,000 containers 
Chance of microbial contamination being killed
during manufacture
The pharmaceutical industry uses steam sterilisation
cycles with high temperatures and long holding times to
ensure that there is a very high chance that all microbes,
including temperature-resistant spore-bearing bacilli, are
killed. However, much lower temperatures and times will
kill many of the type of microorganisms found in
cleanrooms. Similarly, some radiation, chemical and
filtration treatments will also kill many of the cleanroom
microorganisms.
Some aseptic production processes include stages
where microorganisms are killed or eliminated. If, for
example, products are held in an antimicrobial solution, or
raised to a sufficient temperature, then vegetative, or even
some of the mesophylic spore-bearing microorganisms of
the type found in cleanrooms, may be killed.
Consequently, a smaller number of products will be
contaminated by microorganisms at the conclusion of
manufacture, and the likelihood of a patient receiving a
contaminated pharmaceutical product is reduced.
Microorganisms found in pharmaceutical cleanrooms
come almost entirely from people. They are mostly
vegetative bacteria, with occasional yeasts9, 10. Mesophylic
spore-bearing bacteria are also occasionally found in
cleanrooms, these being much more difficult to kill. It is
the principal author’s experience that the proportion of
spore-bearing bacteria is likely to be between 1 in 100 and
1 in 500 of all the microbes found in cleanrooms. It is also
the principal author’s experience that spore-bearing
bacteria can be reported more frequently, but this is likely
to be caused by identification methods that fail to confirm
spore production and mistakenly identify some Gram-
positive rods as Bacillus species.
Inspection of records at AstraZeneca, Macclesfield
shows that 10 out of 1865 microorganisms isolated from
production areas, and identified, were spore-bearing
bacilli i.e. 1 in 187, or a proportion of 5.4 × 10-3. Shown in
Table 2 is the proportion of microorganisms likely to
survive different treatment processes; these proportions
are termed in this paper as survival factor scores. If there
is no stage in the process that uses heat, chemical, or
radiation treatment then the microbial survival factor is
taken as 1, i.e. all will survive. If the treatment is effective
against vegetative microbes, the proportion of microbes
likely to survive is the same as the proportion of spore-
bearing bacilli present i.e. its survival factor score is
between 10-2 and 10-3 (our value is 5 × 10-3, as discussed
above). If the treatment is effective against spores then the
proportion of microorganisms that survive i.e. its survival
factor score, will be less than 10-3.
The values in Table 2 give an indication of the
proportion of microorganisms likely to survive a process,
and can be used if no better information is available, or
sought. A better estimate can be obtained by simulating, in
the laboratory, the steps of the process where micro-
organisms might be killed. Suitable test microorganisms,
typical of the type found in a cleanroom, should be used:
• a vegetative bacteria such as Staphylococcus epidermidis
(NCTC 11047, equivalent to ATCC 14990),
• spores from a mesophylic spore-bearing bacteria such
as Bacillus atrophaeus (ATCC 9372, equivalent to
NCIB 8058), previously known as Bacillus subtilis
var. niger and prior to that as Bacillus globigii. Its
spores have been demonstrated to have mid-range
thermal death characteristics similar to the type of
bacterial spores found in manufacturing cleanrooms11.
• any other microorganisms considered to be a problem
within the manufacturing area.
The test microbes should be incorporated into the product
and counts taken before and after a simulation of the
treatment, and the proportion of surviving micro-
organisms determined so as to obtain a survival factor
score.
Two examples of how the survival factor score might
be determined are as follows:
Example 1 (first continuation): In the previously
Table 2. Approximate survival factor scores and associated
treatments.  
Type of heat, chemical or Microbial survival
radiation treatment factor
No anti-microbial treatment 1
Heat, chemical, or radiation 
treatment effective against 
vegetative microbes between 10-2 and 10-3
Heat, chemical, or radiation likely to be less 
treatment effective against spores than 10-3
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considered Example 1, it was known that there was no
heat, chemical, or radiation treatment applied to the
product that would reduce the microbiological
population. Therefore, the survival factor score was taken
as 1 and the proportion of product contaminated remains
as before.
Example 2 (first continuation): In the previously
considered Example 2, it was known that at the end of the
process the product was heated to 100°C to remove
solvent contained within it, and this was considered to kill
all vegetative bacteria. The spore-bearing bacteria in the
cleanroom occurred as 1 in 200 of the total microbial
flora, i.e. a proportion of 5 × 10-3. It can be firstly assumed
that no vegetative bacteria, but all of the spores would
survive, and therefore a survival factor of 5 × 10-3 can be
used. However, experiments were carried out that
confirmed the solvent and heat treatment killed all
vegetative bacteria but also 50% of the spore-bearing
bacteria. This gave a likely survival of 1 in 400 i.e. a
survival factor score of 2.5 × 10-3.
In some processes a heat, chemical or radiation
treatment may not be the last stage, and other stages of
production may provide additional contamination risks.
These risks should be calculated separately and the
resultant probabilities added together.
Calculation of the overall chance that a
product contains microorganisms at the
end of manufacture
The overall chance that a pharmaceutical product contains
viable microorganisms at the end of manufacture can be
calculated by the use of Equation 1:
Equation 1
Overall proportion of product contaminated at the end of
manufacture = proportion of products contaminated
during production ×microbial survival factor score
Two examples have been given in the previous sections
where the proportion of products contaminated during
production and the microbial survival factor scores have
been calculated. The chance that microorganisms might be
present in the manufactured product at the end of
production can now be calculated. It should be noted that
both of the examples given assume that the manufacturing
process is carried out in one phase. If the production is a
multi-phased operation then the probability of
contamination should be calculated for each phase and then
added together to give the total product contamination.
Example 1 (second continuation): It was previously
calculated that the proportion of containers contaminated
during production was 2.7 × 10-6 and the survival factor
score was 1. The final proportion of the product likely to
be contaminated at the end of production therefore
remains at 2.7 × 10-6.
Example 2 (second continuation): It was previously
calculated that the proportion of containers contaminated
during production was 5.3 × 10-4 and the survival factor
score was 2.5 × 10-3. The overall proportion of contaminated
product at the end of production can therefore be
calculated as follows:
Overall proportion of product contaminated at the end
of manufacture = (5.3 × 10-4) × (2.5 × 10-3) = 1.3 × 10-6
Therefore, the best estimate that the solid product
considered in Example 2 has microbial contamination at
the end of production is about 1 product in 1 million.
Risk from growth after manufacture
Little consideration has been given in the scientific
literature as to what happens to microorganisms during the
shelf life of the pharmaceutical product. If a product is
contaminated, and remains contaminated during
production then, during its shelf life, the microorganisms
have been shown12 to either:
(a) die,
(b) remain viable but not multiply, or
(c) multiply to as many as 107 microorganisms per ml. 
Products administered to a patient that contain a few dead
microorganisms can be considered harmless, as there is
insufficient toxin to cause harm. Products containing a
few live microorganisms of the type found in cleanrooms
i.e. from the skin of personnel can also be considered
relatively harmless. This is supported by the fact that
between 2.4% and 3.8% of needles used for injection will,
as they pass through the epidermis, inoculate skin bacteria
into the bloodstream13; this is not considered a source of
infection. In addition, it is well established that people are
resistant to microbial invasion, being constantly subjected
to microbial invasion. Everett14 has reviewed this and
reported that, for example, rocking of teeth during eating,
bowel movements, etc, cause bacteria to enter the blood
stream.
If microorganisms multiply in the product during their
shelf life then this radically changes the risk of infection to
patients, as a patient's immunological system has difficulty
in dealing with a high dose of microbes, especially if these
are of a more pathogenic variety. However, people are
surprisingly resistant to invasion by microorganisms. For
example, it is known that manipulation of skin boils will
allow Staphylococcus aureus to enter the blood stream14
and Elek and Conen15 have shown that it needed between
106 and 107 of Staphylococcus aureus injected
intradermally to initiate an infection. Sampling of surgical
sites before closure has shown that hundreds of thousands
of bacteria can be introduced into the wound during
surgery without sepsis occurring16, 17. However, the model
we propose assumes that if a pharmaceutical product
contains a large dose of microorganisms it presents a risk
of infection to all patients.
Whyte et al12 studied the growth of microorganisms in
aseptically manufactured pharmaceuticals. Such
pharmaceuticals were inoculated with a range of test
microorganisms associated with the contamination of
pharmaceutical products. It was found that:
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• the majority of microbes died in the container within
4 weeks,
• Gram-negative bacteria were much more likely to
grow than Gram-positive bacteria,
• an inoculum of a few bacterial cells could multiply to
levels of up to 107/ml,
• the presence of preservatives influenced the
likelihood of growth; 12 out of 19 (63%) of the
pharmaceuticals without preservatives supported
growth of one or more microorganisms; only 3 out of
24 (13%) of those with preservatives supported
growth.
For microorganisms to multiply, they require water,
nutrition, and the absence of antimicrobial substances.
Aseptically prepared products can be tested to determine if
a product contaminated during manufacture will support
microbial growth. The test suggested12 is similar to the
pharmacopoeial tests used to ascertain the efficacy of
antimicrobial preservatives18, 19 but differs in that a small
inoculum of test microorganisms of the type that might be
found in the cleanroom environment is used. A 0.1ml
inoculum of a 104 organisms/ml of thoroughly-washed
bacterial cells is added to the product and the ability of the
bacteria to grow, survive, or die over a period of up to 4
weeks at a temperature between 20°C and 25°C is
determined. The determination of the growth of test
microbes in a given product, along with a knowledge of the
proportion of microbes in the cleanroom that are similar to
the test microorganisms, can be used to determine the
chance of microbes multiplying in the product. 
The microbial flora of a cleanroom is predominantly
made up of Gram-positive bacteria with a small proportion
of Gram-negative bacteria. Gram-positive bacteria are
generally much more fastidious in their growth requirements
than Gram-negative bacteria and therefore much less likely
to grow in pharmaceutical products. Consequently an
aqueous solution, or emulsion, that supports the growth of
Gram-positive bacteria typical of many of the microbes
found in a cleanroom e.g. Staphylococcus epidermidis
(NCTC 11047, equivalent to ATCC 14990) is likely to
support the growth of many other microbes in a cleanroom
and the product is at high risk. Because of this, a growth risk
score of 1 i.e. all will grow, may be allocated. 
Gram-negative bacteria will grow in products that do
not support Gram-positive bacteria, as they can grow in
low concentrations of nutrition, and even in solutions of
preservatives12. However, Gram-negative bacteria are less
common in the cleanroom environment. Out of 1865
isolates identified in AstraZeneca in Macclesfield, 11
were Gram-negative i.e. a proportion of 5.9 × 10-3.
Acinetobacter species are the most frequent of the Gram-
negative skin microorganisms found in cleanrooms9 and
Acinetobacter lwoffii (NCTC 5866, equivalent to ATCC
15309) can be used as a suitable test organism. If an
aqueous solution or emulsion supports the growth of this
Gram-negative test organism, it is reasonable to assume
that most Gram-negative bacteria are likely to grow in the
product. The proportion of microbes that are likely to
grow can therefore be taken as the proportion of Gram-
negative bacteria in the cleanroom i.e. about 5.9 × 10-3,
and this should be allocated as the growth risk score.
In Whyte's experiments, Burkholderia cepacia (NCTC
10743, equivalent to ATCC 25461) was the most
aggressive grower and would grow when no others would.
This fact, and the low frequency of occurrence of this type
of microbe suggests that if this organism grows in a
product a growth risk score of about 1 × 10-4 should be
allocated.
Products that will not support the growth of any of the
test organisms will have a very low chance of supporting the
growth of any microbes typically found in the cleanroom.
The allocation of a growth risk score of less than 1 × 10-4 for
this type of product is a reasonable starting point. The score
can then be refined by using a risk assessment of the
likelihood of microbial growth with respect to the nutritional
and antimicrobial properties of the product.
For microorganisms to multiply, they require water.
Oils, water-free ointments, powders, freeze-dried, and any
other water-free pharmaceutical products, will not support
the growth of microorganisms, which will be suspended in
animation, or die. The allocation of a growth risk score of 1
× 10-4, or less, for these types of products is a reasonable
starting point. If the product is freeze-dried there is a small
possibility of growth of microorganisms before freeze-
drying. However, this is unlikely because of the restricted
time, the bacterial lag phase, the low growth temperature,
and possible poor nutrition of the product; this is the
experience of the principal author. However, this
likelihood can be determined by carrying out the growth
tests suggested above on the product prior to freeze-drying,
using as an incubation time the time between filling and
freeze-drying, and an incubation temperature close to room
temperature. Proper statistical methods should be used to
demonstrate a significant increase in growth.
Table 3 gives estimates of the proportion of microbes
found in a cleanroom that are likely to grow in different
products i.e. microbial growth risk scores. This can be
used during the design of the manufacturing process, as
the actual type and proportion of microorganisms to be
found during manufacture will not be known. However,
the growth risk scores given in Table 3 are
approximations to be used if firm data is not available, or
sought. A more accurate estimate of risk can be obtained if
the actual microorganisms isolated during manufacture
are tested to see if they will grow in the product. The
microorganisms used should reflect their exact proportion
of occurrence in the cleanroom environment. The
proportion that grows in the product can then be used as an
accurate estimate of the microbial growth risk score. Thus,
if 2 out of 100 microorganisms isolated in the cleanroom
environment were found to grow in a product, the
microbial growth risk score is 2 × 10-2.
Overall assessment of product risk prior
to patient administration
The overall microbial risk to patients through infection
can now be assessed. By combining:
(a) the proportion of products containing micro-
organisms at the end of manufacture, and 
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(b) the ability of microbial contami-
nants to grow in a pharmaceutical
product during its shelf-life, an
overall risk to patients from
infection can be obtained. This is
shown in Equation 2, with the risk
to patients being considered as the
probability that a product contains
a large dose of microorganisms
prior to administration to the
patient:
Equation 2
Risk to patient = proportion of products
containing microorganisms after
manufacture × proportion of product
that will support microbial growth i.e.
growth risk score
The two risk factors are best entered
into the equation as proportions i.e. 1 in
a million should be entered as 1 × 10-6,
and total risk to patients given in the same style. By taking
a negative value of the logarithm of the total risk to
patients, a simpler value can be obtained and known as a
'Patient Risk Index' e.g. 1 × 10-6 gives a Patient Risk Index
of 6. It should be noted that the higher the Index number,
the lower the risk to the patient.
Two examples of how this can be calculated are now
given:
Example 1 (third continuation): The product considered
in the previous Example 1 was estimated to have a
proportion of contaminated containers at the end of
production of 2.7 × 10-6. It was known that the product
was an aqueous product and it was found that one
microorganism out of 997 isolated from the cleanroom
environment would grow in the product i.e. a proportion
of approximately 1 × 10-3; this is the microbial growth risk
score.
The total risk to the patient, which is the probability
that the product at administration will contain a large
dose of microorganisms is calculated as follows:
Risk to patient = 2.7 × 10-6 × 1 × 10-3 = 2.7 × 10-9
Therefore, the Patient Risk Index = – log [2.7 × 10-9] = 8.6
Example 2 (third continuation): The product considered
in the previous Example 2 was found to have an estimated
contamination rate at the end of production of 1.3 × 10-6
The product was freeze-dried and hence there should
be no growth during the shelf life. It was also
demonstrated that there would be no growth of microbes
in the product prior to freeze-drying. However, the few
microorganisms held in suspended animation might have
a small amount of patient risk and hence a microbial
growth risk score of 1 × 10-5 was allocated and the risk to
patients calculated as follows:
Risk to patients = 1.3 × 10-6 × 1 × 10-5 = 1.3 × 10-11
Therefore, the Patient Risk Index = – log [1.3 × 10-11] = 10.9
Discussion
The object of this paper is to provide a method to assess
the microbial risk to patients receiving aseptically
produced pharmaceuticals. No predictive model exists at
present. The probability of a patient being at risk is
considered to be dependent on whether or not the product
is contaminated during production, and whether its
formulation allows the growth of microorganisms during
the shelf life.
The first component of the risk assessment model is the
proportion of products likely to contain a microorganism
at the end of production i.e. before storage. This
probability is dependent on the chance of a microbe being
deposited or entering a product during manufacture, and
the chance that any microbe introduced will be killed or
eliminated by some step in the process that has sufficient
heat, chemical or radiation. The second component of the
risk assessment model is the chance that the microbes
introduced during production will survive and grow in the
product during the shelf life. Methods are given by which
these proportions can be calculated. These two
proportions are multiplied together to calculate the risk to
patients from infection. If several production phases are
involved in the manufacturing operation then all the
contamination probabilities must be calculated and added
to obtain an overall risk. A Patient Risk Index may then be
calculated.
Evidence is presented in this paper to show that
patients are unlikely to be at risk from a few microbes
administered with a product, as the human body
continually deals with the entry of microorganisms.
Patients with an unimpaired immunological system can
also deal with relatively large doses of microorganisms of
low and even high pathogenicity. However, the basis of
the Patient Risk Model is that patients are at risk if they
receive a product with a large dose of any type of
microorganism.
The proposed model does not consider individual or
unusual risks but predicts the risk to the whole patient
Table 3. Approximate growth risk scores given in relation to the type of product and its
ability to support growth of different types of microbes.
Pharmaceutical formulation Risk of growth associated Microbial growth 
with formulation and test risk score 
organisms
aqueous solution, or emulsion Staphylococcus epidermidis 1
grows – high risk of product 
supporting growth of many 
microbes found in cleanroom
aqueous solution, or emulsion Acinetobacter lwoffii grows – about 5 x 10-3
some microorganisms in 
cleanroom will grow – some risk
aqueous solution, or emulsion Burkholderia cepacia grows – about 1 x 10–4
only very few species of microbes 
will grow – low risk
aqueous solution, or emulsion No microorganisms grow – ≤ 1 x 10-4
very low risk
freeze-dried / powder/ oil / no growth likely – very low risk ≤ 1 x 10-4
water-free ointment
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population. Thus, it is possible that a proportion of
immuno-compromised patients may be infected with a
small dose of microbes. However, the basis of the model
i.e. a large dose of microbes is a danger to a patient, still
applies to immunological deficient or similar patients,
although the model may underestimate the risk.
The Patient Risk Model assumes that aseptically
manufactured products may be occasionally contaminated
during manufacturing. As long as personnel are involved
in the manufacturing process, they will disperse microbes
into the environment and there will always be a risk,
however small, of products being contaminated. Sterility
of all products is impossible. However, it was calculated
in two examples given in the paper that the risk of a
patient receiving a large dose of microorganisms, was in
the region of 1 in 109 to 1 in 1011. This is very reassuring,
especially when compare to the high chance of
contamination occurring during administration of the
product to the patient20.
The risk model discussed in this paper can be used to
calculate the patient risk in the product design stages. The
risk of a formulation supporting growth can then be
optimised to reduce the risk. The manufacturing process
and facility can also be designed to reflect the type of
product and to minimise the microbial risk within the
facility. The risk model can also be used in an established
cleanroom manufacturing operation to assess and
optimise the process to minimise microbial contamination
and ensure that the risk is adequately controlled and
monitored; methods for managing risk in a manufacturing
cleanroom are described elsewhere8. Finally, it is also
clear that the regulatory authority resources are not
infinite. If, as implied in a recent FDA publication22, more
scrutiny should be reserved for the facilities where the
product is most at risk, an assessment using the above
method should be of assistance.
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